Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., (GLOBE NEWSWIRE) -- SpringWorks ...

The company’s novel MAPK-targeted asset, IK-595, is progressing well in its Phase 1 dose escalation ... It is focused on developing novel cancer therapies targeting key signaling pathways that drive ...

Liver diseases, both acute and chronic, continue to pose significant clinical challenges due to high morbidity and mortality ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

Upon binding, these receptors initiate pro-inflammatory signaling pathways such as the NF-κB and mitogen-activated protein ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Researchers conducted a study to determine if variations in the MTNR1A gene, specifically the MRNR1A variant (rs374152717), could be a genetic cause of idiopathic osteoporosis.